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Abstract 
Cortical superficial siderosis (cSS) is a common feature in patients with cerebral amyloid angi-
opathy (CAA). The correlation between β-amyloid and/or tau pathology and the occurrence of 
cSS is unclear. We report on an 80-year-old male patient who was diagnosed with probable 
CAA according to modified Boston criteria and underwent longitudinal magnetic resonance 
imaging, amyloid positron emission tomography (PET), and additional tau PET imaging. Amy-
loid deposition presented predominantly in the contralateral hemisphere not affected by cSS. 
In contrast, tau deposition was predominantly overlapping with brain regions affected by cSS. 
Amyloid deposition was not different in the vicinity of cSS whereas tau depositions were 
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elevated in the vicinity of CSS-affected regions compared to non-cSS-affected brain regions. 
This case of probable CAA suggests that cSS may be associated with a locally elevated tau 
pathology but not with increased fibrillary amyloid deposition. © 2020 The Author(s) 
 Published by S. Karger AG, Basel 
Introduction 
Cerebral amyloid angiopathy (CAA) is a vascular disease with the neuropathological evi-
dence of β-amyloid (Aβ) deposition in the walls of the cortical and leptomeningeal vessels [1]. 
The clinical presentation includes intracerebral macrohemorrhages and cerebral microbleeds 
[2]. Cortical superficial siderosis (cSS) occurs in the majority of patients with histopathologi-
cally proven CAA [3]. The regional interrelation between Aβ and/or tau depositions and the 
presence of cSS is not yet understood.  
Case Report/Presentation 
We report on an 80-year-old male patient who suffered a cryptogenic ischemic stroke in 
the right cerebellum in April 2012. The patient was included in the longitudinal Determinants 
of Dementia after Stroke (DEDEMAS) study [4] and underwent serial standardized magnetic 
resonance imaging (MRI) in combination with 18F-florbetaben [5] Aβ positron emission to-
mography (PET) at 6 months according to the study protocol (NCT01334749). Amyloid PET 
at baseline demonstrated mild positivity. At the follow-up visit in 2015 the patient demon-
strated an incident mild cognitive impairment diagnosed by Petersen criteria [6] and an inci-
dent focal cSS. A diagnostic lumbar puncture revealed reduced Aβ levels (Aβ42 = 279 pg/mL), 
a reduced Aβ42/40 ratio (3.8%), and a normal total tau level (378 pg/mL) in CSF. 
The follow-up MRI in 2017 showed a progression of cSS from focal to disseminated and 
twelve incident cerebral microbleeds restricted to lobar regions in the right hemisphere. 
Hence, a diagnosis of probable CAA according to modified Boston criteria [2] was made. All 
cSS-affected sulci were segmented using ITK-Snap for analysis as previously described [7]. 
The patient further underwent a follow-up Aβ PET and 18F-PI2620 tau PET [8] in 2017/2018. 
Follow-up Aβ PET 6 years from baseline demonstrated a tremendous increase of fibrillar 
amyloid deposition predominantly in the contralateral left hemisphere not affected by cSS 
(Fig. 1a). In contrast, tau deposition was predominantly localized to the right hemisphere 
partly overlapping with brain regions affected by cSS. This was also reflected by plotting 
asymmetry of tau PET against Aβ PET (Fig. 1b, c) demonstrating an opposite dominance of 
amyloid and tau deposition. We further performed a segmental analysis of single brain regions 
affected by cSS (Fig. 2a) and found that amyloid deposition was not different in the vicinity of 
cSS compared to other compartments (Fig. 2b). In contrast, tau depositions were elevated in 
the vicinity of cSS-affected regions compared to non-cSS-affected brain regions (Fig. 2b).  
Discussion/Conclusion 
Previous literature has suggested that cSS represents a more severe stage of CAA [9] and 
is associated with amyloid positivity in patients with probable CAA [10]. However, to the best 
of our knowledge, there is no data available analyzing the distribution of cSS in association 
with local amyloid positivity and there is no data at all on cSS and tau pathology. Now, our 
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observations raise the possibility that cSS in probable CAA may be associated with a locally 
elevated tau pathology but not with increased fibrillar amyloid deposition measured by Aβ 
PET. However, this hypothesis needs to be proven by clinical studies including histology sam-
pling. 
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Fig. 1. Comparison of asymmetries between cSS, β-amyloid (Aβ) and tau. a Axial slices show progression 
of cSS and amyloid positivity between 2012 and 2017/2018 by MRI and PET imaging and tau distribution 
by PET in 2018. b Scatter plot of asymmetry in Aβ PET (2018) in comparison to asymmetry in tau PET for 
all 23 cortical regions (frontal, parietal, temporal) defined by the Hammers atlas. Asymmetry indices 
demonstrate predominant tau positivity in the cSS-affected right hemisphere and predominant Aβ posi-
tivity in the non-cSS-affected left hemisphere. c Statistical comparison of frontal, parietal, and temporal 
asymmetry indices (AI = (L–R)/(L+R)) between Aβ PET and tau PET. p values were derived from a paired 
Student’s t test. 18F-florbetaben Aβ and 18F-PI-2620 tau PET were acquired from 90 to 110 min p.i. and 
from 30 to 60 min p.i., respectively, and each summed to a single static frame. PET values were calculated 
as standardized uptake value ratios with the cerebellar gray matter (CBL) as a reference region after trans-
formation in the MNI space. cSS segmentation and tau PET images are projected onto the patient’s 3D T1W 
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Fig. 2. Segmental analysis based on cSS. a Axial images illustrate delineation of a right temporal cSS area 
and the definition of cSS-positive (black), cSS-negative (gray), and contralateral segments (white) of the 
anterolateral inferior temporal lobe, illustrated in PET image data upon the patient’s T1 MPRAGE MRI.  
b Comparison of PET quantification by standardized uptake value ratios (SUVr) in segmented contralateral 
(white), cSS-negative (gray), and cSS-positive (black) regional values for Aβ PET and tau PET. A total of 17 
cortical regions (defined by the Hammers atlas) affected by cSS were included in the analysis. p values 
were derived from an unpaired Student’s t test. A filter of 5.0 mm was used prior to definition of cSS-posi-
tive voxels to account for the lower PET resolution in comparison to that of MRI. 
 
